79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 58

79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery

79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery

Background/Significance

Finding significant pathologic lesions after reduction mammoplasty is a rare occurrence, with a rate of around 3.5%. The incidence of these findings has been found to be higher in patients aged older than 40 years. These findings are also rare in gender affirming surgeries, most of which have been reported in case reports. One study found an incidence of 0.7% for incidentally found high-risk or malignant lesions, with higher rates in patients over 25 years old. Another noted that 67% of breast cancer found in transmen were identified after gender affirming mastectomies, with over half found incidentally. Most studies have focused on incidence rate and management after surgery. For this study, we planned to additionally review preoperative imaging, focusing on patients younger than 40 years who would not have started routine mammograms.

Materials and Methods

A retrospective chart review was performed on female patients between the ages of 18 and 40 years old who underwent non-oncologic breast surgery between 2019 and 2024 and were found to have abnormal findings on pathology. Data collected included demographics, imaging, breast density, surgeries performed, tumor characteristics, stage at diagnosis, genetic testing, and follow-up recommendations.

Results

A total of 14 patients were identified. All were female patients with ages ranging from 18 to 37 years. Four patients had bilateral mastectomies for gender dysphoria, while the remaining patients had bilateral breast reductions. One patient had previous ultrasounds performed for an abscess. Four patients had a family history of breast or ovarian cancer. Two patients were found to have invasive ductal carcinoma (IDC), 2 had ductal carcinoma in situ (DCIS), 7 had atypical ductal hyperplasia (ADH), and 3 had atypical lobular hyperplasia (ALH). Of the patients who had bilateral mastectomies, 1 patient had DCIS. MRI and breast surgery follow-up was recommended, but there was no evidence of follow-up in the medical record. Ten patients were recommended to have additional imaging, of which, 6 patients had imaging performed. Six patients subsequently had genetic testing performed. Two patients underwent additional surgery for their diagnosis (1 with IDC and 1 with DCIS). The 3 patients who underwent bilateral mastectomies and were found to have ADH only had follow-up with plastic surgery. One patient with ALH found after bilateral reductions was recommended to follow up with their primary care physician. The remaining patients were referred to breast surgery.

Conclusion

Our results over a 5-year period showed a small number of patients younger than 40 years old who had incidental high-risk or cancerous lesions found on pathology following breast reduction or gender affirmation surgery. Of these 14 patients, only 1 had any imaging performed prior to surgery but for unrelated reasons. All except 1 patient were appropriately referred to breast surgery postoperatively, though it could be argued that the 3 patients with ADH after gender affirming mastectomies should be followed for their high-risk lesions, as more breast tissue is typically left behind after mastectomies for gender affirmation compared with those performed for cancer. Our study does not provide sufficient evidence to recommend routine screening prior to breast plastic surgery for diagnoses unrelated to cancer. Though it is something plastic surgeons should keep in mind, especially for high-risk patients.

Articles in this issue

3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.